Mackay Shields LLC’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Mackay Shields LLC’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,400	Closed	-$1.22M	–	1647
2020 Q1	$1.22M	Buy	25,400 +4,000	+19%	+$186K	0.01%	877
2019 Q4	$1M	Buy	+21,400	New	+$946K	0.01%	1067

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Mackay Shields LLC's RARX Position: Q2 2020 in Review

Mackay Shields LLC sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 25,400 shares — an estimated $1.22M sold.

Mackay Shields LLC first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $1.22M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Mackay Shields LLC reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Mackay Shields LLC sold 25,400 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.22M.
Mackay Shields LLC first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Mackay Shields LLC's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.22M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Mackay Shields LLC's 13F filing for Q2 2020, filed 31 Jul 2020.